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Abstract
Introduction: Neurocognitive disorders (NCDs) are distur-
bances highly related to age. This means that, with the in-
creasing trend in life expectancy, there is also an increase in 
this diagnosis, although NCDs are not exclusively found in 
the population over 65 years old. Likely, they will increase in 
the coming years together with improvements in diagnosis. 
In addition to the use of medicines and rehabilitative tech-
niques, pet therapy is also used. Pet therapy makes use of 
animals with therapeutic, rehabilitative, educational, and 
recreational purposes for people affected by physical, neu-
romotor, and psychiatric disorders. Pet therapy seems to be 
functional for increasing social and communication compe-
tencies, facilitating verbal and body language, increasing 
self-esteem, improving quality of life, and reducing anxiety/
stress. Methods: This study was based on scientific papers 
and publications obtained from the PubMed and Google 
Scholar databases. Moreover, other articles from further 
cross-references were included. Specific database research 
criteria were (a) articles published in 2018 or later, (b) sam-
ples containing only adults over 65 years old, (c) written in 
English or Italian, and (d) on the topic of animal-assisted in-
tervention. Results: Uncertain results were obtained. Al-
though a positive effect was found, the included articles 
were of insufficient methodological rigor. Discussion/Con-
clusion: Although many studies reported positive results, 
these could not be generalized because of the numerous bi-
ases present (e.g., small sample size, lack of methodological 
rigor, lack of protocol, etc.). Future studies, therefore, should 
seek to address the limitations found in the analyzed studies.
© 2021 The Author(s).
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Introduction
As individuals age, they experience inevitable physio-
logical and emotional/cognitive changes that can lead to 
changes in social interactions. In principle, all individuals 
over 65 years of age are defined as “elderly”; this age lim-
it has been set quite arbitrarily [1]. Gerontologists gener-
ally divide the population over 65 years of age into 3 
groups: the group between 65 and 74 years of age is de-
fined as “young elders,” the one between 75 and 84 years 
of age defined “elderly elders,” and finally the last one 
defined by “ultra-elders” over 84 years of age [1].
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Epidemiology
Mental health is related to physical and cognitive 
problems, which people can experience throughout 
their life. The elderly population experiences more 
problems than all other age-groups [1]. According to the 
National Academy on an Aging Society [2], 80% of the 
elderly population suffers from at least one major med-
ical condition. Neurocognitive disorders (NCDs) [3] are 
age-related disorders, and this means that as the years of 
age increase, there is also an increase in this kind of di-
agnosis; according to ISTAT (2014), about 600,000 peo-
ple in Italy have a NCD due to Alzheimer’s disease or 
dementia. Worldwide, life expectancy is increasing and 
with this also the elderly population; in 1990, 
<200,000,000 people were aged ≥65 years, while current 
prognoses suggest that, in 2030, this population will ex-
ceed 1,300,000,000, increasing overall by 180% [4]. In 
2017, according to a World Health Organization (OMS) 
report, 5–8 out of 100 people are suffering from NCD, 
with some 50 million people affected globally [5]. It is 
estimated that the number of people with NCD world-
wide will increase at a rate of 10 million per year and that 
the total population with a NCD will reach 82 million by 
2030 and 152 million by 2050 [6]. The study of NCD 
shows an increase in cases even in youth, but it is undis-
puted that the majority of cases are observed in the pop-
ulation over 65 years of age. This phenomenon is related 
to the constant increase in the average life span of the 
population, which is also measured by the aging index, 
that is, the ratio between the number of elderly people 
(age >65 years) and the number of young people (age 
<15 years). In Italy, the aging index shows >144 elderly 
people for every 100 young people [7]. NCD is a pathol-
ogy that involves the individual in its entirety (some of 
the areas involved are memory, language, thought, mo-
bility, sleep-wake rhythm, attention, thought process-
ing, etc.) [8] and becomes highly debilitating. From the 
pharmacological point of view, there are no products 
that can reverse this pathology, but current drug therapy 
can slow down the progress of the disorder by delaying 
degeneration and neuronal death [6].
Pharmacotherapy
The pharmacological approach does not aim to act on 
the causes of the disease, but rather on the evident symp-
toms of the patient. Generally, drugs act on the following 
functions: cognitive, behavioral, disability, and for the 
improvement of quality of life. To counteract the symp-
toms of NCD, anticholinesterase drugs and nootropic 
drugs are used [8]. In addition to using drugs to combat 
cognitive impairment in NCD, drugs are often used to 
mediate the symptoms of psychotic and behavioral disor-
ders. Studies have confirmed that, during the disease, pa-
tients with NCD also show symptoms beyond the cogni-
tive sphere, which are mainly responsible for burnout in 
caregivers [8]. Generally,  psychopharmacological ap-
proach is adopted, that is, using a drug of known efficacy 
for the symptoms that are most similar to those presented 
by the patient. As mentioned above, for NCD, there is no 
cure with pharmacological treatments and they are not 
able to bring about symptomatic reduction of the disease 
to slow its progress. Also, drug treatments can have nega-
tive side effects [9]. For this reason, there is a need to 
implement nonpharmacological treatments in order to 
offer alternatives [10].
Pet Therapy
In the field of nonpharmacological therapies, pet ther-
apy can also be a good way forward. This nonpharmaco-
logical therapy is defined as a useful, versatile, and poten-
tially effective tool, also in terms of cost, to mitigate the 
symptoms of the disorder and to improve the quality of 
life of subjects with NCD and their caregivers [11]. This 
is due to the fact that, with the worsening of NCD, the 
ability to communicate verbally and comprehension is 
reduced, but through pet therapy, communication can be 
stimulated despite these difficulties. This is due to the re-
ception and interpretation of stimuli and signals such as 
visual, tactile, auditory, and olfactory. In the elderly, the 
presence of animals can often evoke positive memories, 
for example, links with animals they had previously [12]. 
A study by Odendaal and Meintjes [13] observed that 
contact with animals leads to increased concentrations of 
endorphins, oxytocin, prolactin, phenylethylamine, and 
dopamine and reduced plasma cortisol levels. Oxytocin 
has widespread neurological, biological, emotional, and 
social effects, including attachment and social processes, 
decreases anxiety, stress, and aggressive behavior [14]. It 
also stimulates the parasympathetic nervous system, re-
duces the secretion of cortisol, aldosterone and adrena-
line, increases pain tolerance, lowers blood pressure, de-
creases inflammation, improves wound healing, and fa-
cilitates learning [15].
The primary objective of this work was to understand 
the effects of pet therapy in elderly patients with NCD. 
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Another aim was to provide a further empirical basis for 
this topic and to identify the obstacles encountered so far 
in research, in the hope of providing further elements to 
help overcome them in future studies.
Methods
The material for the systematic review of the literature on pet 
therapy and NCD was found in the databases Google Scholar 
and PubMed; the words used were “Animal assisted interven-
tions” AND “Pet therapy” AND “Neurocognitive disorder” 
AND “Over 65s.” The PRISMA method was used to find the ar-
ticles. The articles must meet the following inclusion criteria: a 
limit was set for the publication year, conventionally defined as 
2018 (the date of the first meta-analysis dealing with animal as-
sisted intervention [AAI] in general), which allowed us to ana-
lyze the most recent findings on the subject (from 2018 to 2020, 
inclusive). The articles must deal mainly with assisted interven-
tions with animals as the topic, written in English or Italian, and 
concern a population of elderly people only (i.e., 65 years old or 
older). Although NCD can also affect younger individuals, NCD 
primarily involves this type of population. Articles using any 
type of animal were included. The list of studies identified by the 
search engines was screened by reading (by the researcher CS) 
the titles and abstracts of the studies. Once this step was taken, 
the results of searches in the 2 databases were integrated. In the 
first phase of research, 5,058 articles were selected, and at the end 
of the selection process, a total of 12 articles were obtained. The 
articles were skimmed using the abovementioned criteria to-
gether with the reading of the titles and abstracts’ an additional 
2 articles that met the inclusion criteria were found through 
cross-referencing. The flowchart (Fig. 1) shows the whole skim-
ming process, while Table  1 describes the articles included in 
this review. In addition, the distribution of the countries where 
the studies were conducted is shown in Figure 2.
Results
In the selected studies included within this review, the 
following areas were analyzed: quality of life (n = 7), 
mood (e.g., depression and emotional well-being; n = 6), 
social function (n = 6), Behavioral and Psychological 
Symptoms of Dementia score (n = 3), symptoms closely 
related to NCD (n = 3), agitation and irritability (n = 5), 
cognitive state (n = 8), physical functions (e.g., motor ac-
tivities, daily activities, diet, and sleep; n = 5), and adverse 
effects (n = 3). One study took into account the severity 
of the disease, mortality, and stress to the caregiver and 
the animal. These studies indicated a positive effect of the 
use of pet therapy; for example, the study conducted by 
Peluso et al. [19] states how human-animal interaction 
has positive effects by promoting self-esteem, improving 
cognitive performance such as memory or concentration, 
motor skills, and quality of life, and also decreases the ef-
fects of symptoms due to NCD. A study by Wesenberg et 
al. [12] also showed that the use of AAI leads to an in-
crease in well-being in nursing home residents with NCD, 
increasing social interaction and emotional well-being. 
However, in some studies, there were no significant 
changes with respect to the areas investigated, but this 
aspect can be considered a remarkable achievement gave 
the progressive nature of the disorder [18]. However, de-
spite the positive expectations, there was a common 
thread to all of the studies considered, which is the fact 
that the research was performed with a high degree of bias 
and deficits in research design and, consequently, in the 
execution. Because the results of the various existing 
studies are heterogeneous with considerable variation in 
study design, interventions, participants, baseline re-
ports, and outcome measures, this makes comparison be-
tween studies difficult [12]. This is one of the main com-
ponents that make it impossible to provide valid and cer-
tain conclusions about the effects of treatment through 
AAI, as it leads to controversial and ambiguous conclu-
sions [19].
Databases: PubMed and Google
scholar
Key words: “Pet therapy”, “Animal-Assisted
Intervention” and “Neurocognitive disorder”
(n = 5,058)
From 2018 to 2020; languages included:
Italian and English; >65 years (n = 90)
80 articles were excluded by reading
the title and abstract
(n = 10)
Cross reference (n = 2)
Total articles (n = 12)
Fig. 1. PRISMA: Search and selection guidelines flow chart.
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Discussion/Conclusion
The topic covered in this article shows the willing-
ness and need to develop new methods of intervention 
for alternative NCD and/or support for other types of 
treatment. Pet therapy applied to NCD is an extremely 
recent intervention of psychosocial nature and still in 
the experimental phase; consequently, it is not very 
widespread in the academic and clinical world. Since 
NCD affect a large part of the population, this implies 
a waste of resources, time, and money for its cure. The 
total social cost of DNC is estimated about USD 820 bil-
lion, or 1.1% of the global gross domestic product [26] 
and, taking into account that in recent years an increase 
in this disease has been observed, it can be assumed that 
there has been a corresponding increase in health-care 
costs.
For this reason, it is also important to consider this as-
pect and understand whether AAI is a resource or an ag-
gravation of costs. In recent years, there has been growing 
interest in research in this field [12], but, despite this, the 
state of the art of AAI research applied to NCD is still un-
derdeveloped. The reasons for these difficulties are many 
and among the main one we can include: the obtained 
results, the methodological rigor, the timing of imple-
mentation, and the possibility of carrying out further re-
search. NCD will certainly be one of the most significant 
health problems [21] in coming years, both in terms of 
health costs and the well-being of the person. As already 
pointed out, advancing age increases the risk of finding 
an NCD. The projection of statistical data indicates an 
increase in the diagnosis of this pathology in people over 
65 years of age. Another relevant aspect is that NCD is not 
curable, but only the symptoms of this disease can be 
treated [7], which we have seen involve the functions of 
the individual as a whole.
Generally, the most commonly used treatments are 
pharmacological, which most often leads to side effects 
[10]. No treatment that is clearly and consistently effec-
tive in preventing or stopping the progression of this dis-
order has yet been identified [27]. For these reasons, al-
ternative psychosocial interventions that avoid the use of 
drugs are being sought, and the World Health Organiza-
tion also proposes the creation of plans and programs to 
improve the social well-being and quality of life of all 
those affected by NCD and their caregivers [21]. For this 
reason, one of the possibilities explored is the use of ther-
apy animals, which is generating considerable interest in 
education and health services [25]. Pet therapy, as a type 
of intervention, is not intended to cure the disease, given 
the progressive form of the disorder. It is rather a treat-
ment that can be relied on to induce relief to people who 
are affected and those who care for them, as stated in a 
study by Hu et al. [17]: “our results are not surprising be-
cause dementia is a progressive brain disease and it would 
be unrealistic to expect that the AAI reverses the cognitive 
state in a normal state.” Observing the results of these 
studies clearly shows the mixed nature of the conclusions. 
From many kinds of studies, the positive character of the 




























Fig. 2. Distribution of the countries where 
the studies were conducted.
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conducted by Peluso et al. [19] states that the interaction 
between people and animals has positive effects in terms 
of promoting self-esteem, improving cognitive perfor-
mance such as memory or concentration, motor skills, 
and quality of life while decreasing the effects of symp-
toms due to NCD. Also, the study by Wesenberg et al. [12] 
showed that the use of AAI leads to increased well-being 
in residents of nursing homes with NCD, increasing so-
cial interaction, and emotional well-being. If in some 
studies there were no significant changes compared to the 
investigated areas, this can also be considered a remark-
able result given the progressive characteristic of the dis-
order [18]. However, despite the positive expectations, 
there was a common thread to all of the studies consid-
ered, which is the fact that the research was performed 
with a high degree of bias and deficits in research design 
and, consequently, in the execution. Because the results 
of the various existing studies are heterogeneous with 
considerable variation in study design, interventions, 
participants, baseline reports and outcome measures, this 
makes comparison between studies difficult [12]. This is 
one of the main components that make it impossible to 
provide valid and certain conclusions about the effects of 
treatment through AAI, as it leads to controversial and 
ambiguous conclusions [19].
Although many studies report positive results, these 
cannot be generalized because of the numerous biases 
present (e.g., small sample, lack of methodological rigor, 
lack of protocol, etc.). Nevertheless, these results and the 
urgent need to identify strategies to support drug treat-
ment and to mitigate the side effects of drugs suggest im-
plementing research around this topic. Future studies, 
therefore, should seek to address the limitations found in 
the analyzed studies.
Limits
Some of the limitations found are (i) many of the stud-
ies do not provide details on the implementation of the 
interventions, (ii) they either do not have a control group 
or the control group is also an active group (subjected to 
other types of interventions or they had unanticipated in-
teractions with the animal), (iii) many confounding vari-
ables such as medication intake are present, (iv) timelines 
are short, (v) the sample size is small, (vi) dropouts occur 
during the trial (due to death, relocation or reluctance to 
continue), (vii) the sample is drawn from the same facil-
ity, (viii) there is no indication of the breed of the animal 
and its training, (ix) there is no consideration of whether 
the presence of the coadjutor would affect the outcome of 
the encounters, and (x) the methods of including partici-
pants are often unclear. Based on all these factors, it is 
very difficult to provide consistent and effective conclu-
sions, but by introducing protocols and increasing meth-
odological rigor, these limitations could be overcome.
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